Why MannKind Corporation Stock Was Whipsawed in Late-Day Trading

Fool.com Headlines http://ift.tt/1wSA8pg MannKind and shareholders look rightfully confused following the approval of its lead diabetes drug, Afrezza. See what has investors so worked up following the FDA's decision.